Encompass Health Corp

Encompass Health Corp(EHC)の株式分析

$127.870

+0.102 (+0.08%)終値時点

Loading chart…
高値
129.355
始値
129.130
出来高加重平均価格
128.03
出来高
1.30M
時価総額
8.64B
安値
126.860
売買代金
166.13M
EV/EBITDA(TTM)
9.54

Encompass Health Corporation is a provider of inpatient rehabilitation services. The Company provides specialized rehabilitative treatment, using technology and intensive therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability. It operates hospitals in approximately 39 states and Puerto Rico, with concentrations in Florida and Texas. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver patient care services. It offers neurological, spinal & brain-related rehabilitation, which include brain injury rehabilitation, multiple trauma rehabilitation, neurological rehabilitation, spasticity management, spinal cord injury rehabilitation and stroke rehabilitation. It also offers orthopedic & joint-related rehabilitation, which includes amputee rehabilitation, chronic condition management, hip rehabilitation and orthopedic rehabilitation.

AI分析 of Encompass Health Corp (EHC)

買い

Encompass Health Corp is a good buy right now, trading at $127.87 with a forward P/E of 18.90, which is attractive compared to the industry average. The company has shown strong financial performance with a gross margin of 90.20% and a net income of $208 million in Q2 2026, indicating robust profitability. Analysts have set a price target of $150, suggesting a potential upside of approximately 17.3%. The main risk is the current RSI of 78.09, indicating that the stock may be overbought in the short term, but the overall fundamentals and market sentiment support a long-term investment.

バリュエーション指標

Encompass Health Corp(EHC)の現在の予想PERは18.90で、5年平均は19.22です。

予想PER

適正
5年平均 P/E
19.22
現在のP/E
18.90
割高
21.31
割安
17.14

予想EV/EBITDA

適正
5年平均 EV/EBITDA
10.56
現在のEV/EBITDA
9.54
割高
11.86
割安
9.25

予想PSR

割高
5年平均 P/S
1.50
現在のP/S
1.80
割高
1.75
割安
1.25

Alphio AI による EHC の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%EHC

$164.93

シナリオ価格

基

基本

基本 · 50%EHC

$142.72

シナリオ価格

弱

弱気

弱気 · 25%EHC

$139.75

シナリオ価格

EHC を保有するクジラ

M

Meridiem Capital Partners LP

+ を保有EHC

+3.28%

3か月リターン

T

Trillium Asset Management, LLC

+ を保有EHC

+2.94%

3か月リターン

L

Leeward Investments, LLC

+ を保有EHC

-1.14%

3か月リターン

S

Scout Investments, Inc.

+ を保有EHC

-5.29%

3か月リターン

C

Copeland Capital Management, LLC

+ を保有EHC

-7.87%

3か月リターン

イベントタイムライン

2026-08-05 (ET)

16:30:00

Company Reports Q2 Revenue of $1.6B, Beating Expectations

16:30:00

Raises FY26 Revenue Outlook to $6.41B-$6.49B

2026-07-23 (ET)

08:30:00

Encompass Health Increases Quarterly Dividend to $0.21

2026-05-29 (ET)

08:40:00

Encompass Health to Build 36-Bed Rehab Hospital in West Virginia

2026-05-11 (ET)

16:40:00

Encompass Health to Build 50-Bed Rehab Hospital in Idaho

ニュース

EHC のよくある質問 — Alphio AI が回答

Encompass Health Corporation is a provider of inpatient rehabilitation services. The Company provides specialized rehabilitative treatment, using technology and intensive therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability. It operates hospitals in approximately 39 states and Puerto Rico, with concentrations in Florida and Texas. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver patient care services. It offers neurological, spinal & brain-related rehabilitation, which include brain injury rehabilitation, multiple trauma rehabilitation, neurological rehabilitation, spasticity management, spinal cord injury rehabilitation and stroke rehabilitation. It also offers orthopedic & joint-related rehabilitation, which includes amputee rehabilitation, chronic condition management, hip rehabilitation and orthopedic rehabilitation. It operates in the Healthcare sector (SERVICES-HOSPITALS industry).

Encompass Health Corp is a good buy right now, trading at $127.87 with a forward P/E of 18.90, which is attractive compared to the industry average. The company has shown strong financial performance with a gross margin of 90.20% and a net income of $208 million in Q2 2026, indicating robust profitability. Analysts have set a price target of $150, suggesting a potential upside of approximately 17.3%. The main risk is the current RSI of 78.09, indicating that the stock may be overbought in the short term, but the overall fundamentals and market sentiment support a long-term investment.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める